Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus ADT before and after radical prostatectomy for high-risk localized or locally advanced prostate cancer
NL-OMON54520Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide + ADT with Placebo + ADT (2 arms). Primary endpoints: Pathologic complete response and Metastasis-free survival. Started Jul 2019; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON54520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54520.